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Background: Increased circulating cathepsin S levels have been linked to increased risk of cardiometabolic diseases
and cancer. However, whether cathepsin S is a modifiable risk factor is unclear. We aimed to investigate the effects
of a prudent diet on plasma cathepsin S levels in healthy individuals.
Findings: Explorative analyses of a randomized study were performed in 88 normal to slightly overweight and
hyperlipidemic men and women (aged 25 to 65) that were randomly assigned to ad libitum prudent diet, i.e.
healthy Nordic diet (ND) or a control group (habitual Western diet) for 6 weeks. Whereas all foods in the ND were
provided, the control group was advised to consume their habitual diet throughout the study. The ND was in line
with dietary recommendations, e.g. low in saturated fats, sugars and salt, but high in plant-based foods rich in fibre
and unsaturated fats.
The ND significantly decreased cathepsin S levels (from 20.1 (+/−4.0 SD) to 19.7 μg/L (+/−4.3 SD)) compared with
control group (from 18.2 (+/−2.9 SD) to 19.1 μg/L (+/−3.8 SD)). This difference remained after adjusting for sex and
change in insulin sensitivity (P = 0.03), and near significant after adjusting for baseline cathepsin S levels (P = 0.06),
but not for change in weight or LDL-C. Changes in cathepsin S levels were directly correlated with change in
LDL-C.
Conclusions: Compared with a habitual control diet, a provided ad libitum healthy Nordic diet decreased cathepsin
S levels in healthy individuals, possibly mediated by weight loss or lowered LDL-C. These differences between
groups in cathepsin S were however not robust and therefore need further investigation.
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Introduction
Cathepsin S is highly expressed in antigen presenting
cells [1-3] and has important functions in the major
histocompatibility complex (MHC) class II antigen pres-
entation [4]. Furthermore it degrades extracellular matrix
[5].
Elevated circulating cathepsin S concentrations predict
mortality in elderly men [6] and it has been linked to
cardiovascular disease (CVD), type 1 and type 2 diabetes,
cancer [7-10] and inflammation [11,12]. Cathepsin S
is also associated with LDL-C and HDL-C [13-15]. Fur-
thermore it is increased in adipose tissue and serum* Correspondence: ulf.riserus@pubcare.uu.se
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unless otherwise stated.of obese persons [16,17], whereas studies in obese wo-
men have indicated that weight loss by obesity sur-
gery or energy-restricted diet decrease serum cathepsin
S [17,18].
As cathepsin S appears to be a novel promising risk
marker of both cardiometabolic and malignant diseases, it
is important to examine the effect of diet on cathepsin S
concentrations. We hypothesized that a healthy nordic diet
(ND) could reduce plasma levels of cathepsin S. The aim
was to investigate the effects of a ND, eaten ad libitum, on
plasma levels of cathepsin S in the NORDIET-trial. A
secondary aim was to investigate the relationships between
changes in cathepsin S concentrations and changes in
cardiometabolic risk factors.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Subjects
During December 2007, subjects living in Bollnäs, Sweden,
were recruited by advertisements in the local news-
paper. The inclusion criteria were healthy (as assessed
by a physician), men and women between 25 and 65
years, plasma LDL-C ≥3.5 mmol/L¯1, body mass index
(BMI) ≥20 and ≤ 31 kg m2, for women and men respect-
ively [19]. Subjects with hypertension, CVD, diabetes and
other chronic disease and those on lipid-lowering drugs
were excluded.Study design
The study was conducted between February and May,
2008. Eighty-eight subjects were randomly assigned to
one of two groups: a ND or a control group following
their usual diet.
Clinical and laboratory assessments were performed
at baseline and after 6 weeks. The trial was conduc-
ted in accordance with the CONSORT statement and
registered in the Current Controlled Trials database
(http://www.controlled-trials.com); International Stand-
ard Randomized Controlled Trial Number (ISRTCTN):
77759305.
Written informed consent was given by all subjects.
The study was approved by the regional ethical commit-
tee in Uppsala.Outcome measures
In the present post-hoc study of the NORDIET-trial
we aimed to investigate changes in plasma cathepsin
S levels during ND as compared with a control group. We
also investigated possible relationships between change in
plasma cathepsin S and changes in weight, insulin sensi-
tivity, triglycerides (TG), LDL-C, HDL-C, systolic blood
pressure (SBP) and diastolic blood pressure (DBP).Intervention
All main meals were provided to the subjects in the ND
group. The assessment of diet and the change in diet
during the study has been described previously [19].Prudent diet
The ND was based on the Nordic nutrition recommen-
dations (NNR) [20] and contained characteristic foods
used in Nordic countries including fruits (e.g. apples)
and berries (e.g. blueberries), legumes, vegetables, low-
fat dairy products and fatty fish (e.g. salmon). The ND
also included LDL-C lowering foods (e.g. oats; barley,
almonds and psyllium seeds) [21,22]. The ND was pro-
vided ad libitum.Control group
The subjects in the control group were instructed to fol-
low their habitual diet, eaten ad libitum, and continue
their usual physical activity.
Clinical assessment
Bodyweight was measured (kg) in light clothing without
shoes, on a digital scale. Blood pressure was measured
manually in a sitting position after 5 minutes rest. Two
measurements were performed with a 2 minutes inter-
val, and the average value was calculated.
Biochemical analysis
Venous blood was collected after a 12 h fast and plasma
separated and frozen in −70°C before analyses. Plasma
cathepin S was measured by ELISA (human cathepsin
S (Total), DY1183, R&D Systems). The intraassay CV
was 7%. Glucose, total cholesterol, TG and HDL-C plas-
ma concentrations were measured using a Roche Diag-
nostics Cobas® 6000. Plasma LDL-C was calculated by
Friedewalds formula [23]. Plasma insulin was measured
by an enzyme-linked immunoassay kit (Mercodia AB,
Uppsala, Sweden). Homeostasis model assessment-insulin
resistance (HOMA-IR) was calculated [24].
Statistical analysis
Data are presented as mean ± SD. Per protocol analysis
was used to assess effects of diet on outcome measures.
Unpaired T-test was used to assess differences in plasma
levels of cathepsin S during follow up, between the two
groups, and as a second step, we used ANCOVA to ad-
just for sex, weight and cardiometabolic risk factors. To
assess associations between change in cathepsin S and
change in cardiometabolic risk factors linear regression
and Pearson’s correlation was used. A two-tailed P-value
of 0.05 was regarded as significant. STATA, version 11
was used for statistical analysis.
Results
Only two subjects (one in each group) dropped out [19],
leaving 86 subjects with data on cathepsin S. After ran-
domization, the two groups were almost identical with
regards to the baseline characteristics, with the excep-
tion of a significant difference in cathepsins S levels bet-
ween the groups (Table 1).
Effect of diet on cathepsin S
As previously reported [19], ND reduced body weight
(mean 3 kg) as compared with the control group. Here
we report a significant difference between ND and con-
trol group in the change of cathepsin S concentrations
(P = 0.03 for between group difference, Figure 1).
The ND decreased plasma cathepsin S levels, from
20.1 (+/−4.05 SD) to 19.7 μg/L (+/−4.3 SD) whereas
Table 1 Baseline characteristics after randomization
Characteristics Control group Healthy Nordic diet P-value
Subjects, n 42 44
Age (year) 53.4 ± 8.1 52.6 ± 7.8 0.63
Men/women 15/27 17/27 0.83
Body weight (kg) 78.0 ± 13.3 76.0 ± 10.5 0.44
Body mass index (kg m¯2) 26.5 ± 3.3 26.3 ± 3.2 0.79
SBP (mmHg) 123 ± 14 128 ± 12 0.50
DBP (mmHg) 83 ± 9 81 ± 7 0.16
Plasma TG (mmol/L¯1) 1.4 ± 0.8 1.6 ± 0.8 0.32
Plasma cholesterol (mmol/L¯1) 6.4 ± 0.7 6.2 ± 0.8 0.36
Plasma LDL cholesterol (mmol/L¯1) 4.2 ± 1.0 4.0 ± 0.6 0.33
Plasma HDL cholesterol (mmol/L¯1) 1.5 ± 0.5 1.5 ± 0.4 0.28
LDL/HDL ratio 2.8 ± 1.0 2.9 ± 0.8 0.80
Plasma glucose (mmol/L¯1) 4.9 ± 0.6 4.9 ± 0.5 0.54
Insulin resistance (HOMA-IR) 1.3 ± 0.6 1.2 ± 0.6 0.47
Cathepsin S μg/L 18.3 ± 2.99 20.1 ± 4.1 0.02
Data are means ± SD. HDL: High-density lipoprotein; LDL: Low-density lipoprotein; HOMA-IR: Homeostasis model assessment-insulin resistance; SBP: systolic blood
pressure; DBP: diastolic blood pressure; TG: triglycerides. Differences between the Nordic Diet and Control groups were assessed using unpaired two-tailed t-tests.
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19.1 μg/L (+/−3.8 SD) (Figure 1). Mean difference in
change between groups were 12.0 μg/L (+/−25.2 SD).
These differences remained after adjusting for sex (p =
0.03) and insulin sensitivity (P = 0.03), whereas adjusting
for weight change (P = 0.22), LDL-C (P = 0.36) and total
cholesterol (P = 0.48) abolished the significant differ-















Figure 1 Differences in serum cathepsin S levels between the control
Serum levels of cathepsin S were decreased compared with the control diecathepsin S levels attenuated the difference between
groups (p = 0.06), as well as adjustments for differences
in systolic and diastolic blood pressure (p = 0.06). As de-
scribed previously [19], dietary compliance was overall
excellent and the dietary goals were achieved for most
nutrients”. E.g. total fat was 27%E (goal 25-35%E), carbo-
hydrate 52%E (45-60%E), protein 19%E (10-20%E), fibre
54%E (25–35) and saturated fat 5%E (<8%E).Healthy Nordic diet 
diet and healthy Nordic diet (ND) from baseline to 6 weeks.
t (P = 0.03).
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cardiometabolic risk factors
Changes in cathepsin S tended to be correlated with
changes in weight (P = 0.05), which remained after adjust-
ing for sex (P = 0.04). Furthermore, change in cathepsin S
were correlated with change in LDL-C (P = 0.03) and total
cholesterol (P = 0.01). These associations remained signifi-
cant after adjusting for sex (P = 0.03 and 0.01 respectively).
Change in cathepsin S did not correlate with changes in
insulin sensitivity, TG, HDL-C, SBP or DBP (Table 2).
Discussion
Adherence to an ad libitum ND for 6 weeks slightly de-
creased levels of plasma cathepsin S in normal or slightly
overweight individuals, compared with the control group.
Change in circulating cathepsin S concentrations were
correlated with changes in body weight, LDL-C and total
cholesterol suggesting that these factors may mediate the
effect on cathepsin S levels.
To our knowledge, there are no studies investigating
the effects of a prudent diet on cathepsin S concentra-
tions. In accordance with our results, studies in obese
women, showed that energy restriction and weight loss
reduced cathepsin S mRNA and cathepsin S release in adi-
pose tissue as well as serum levels [17,18]. Body weight
decreased by on average 3 kg during ND [19], and there
was a near significant correlation between the change in
body weight and change in cathepsin S. This study sug-
gests that an ad libitum diet reduces weight and cathepsin
S levels also in non-obese subjects, including men. The
decreased cathepsin S levels did not remain significant
after adjusting for weight change, suggesting that weight
reduction mediated some of the dietary effect on cathep-
sin S. Adjusting for baseline levels of cathepsin S resulted
in a P-value of 0.06 which may indicate lack of statistical
power, rather than a lack of effect on cathepsin S. How-
ever, regression-towards-the mean effect cannot be com-
pletely excluded. Cathepsin S is strongly associated withTable 2 Correlations between change in serum cathepsin S co










Data are correlation coefficients and regression coefficients, with 95% CI. All model
resistance, HDL-C:High-density lipoprotein cholesterol; LDL -C: Low-density lipoprot
blood pressure; Pearson's correlation and Linear regression has been used.cardiovascular risk factors, such as elevated triglycerides
[17] and LDL-C [13]. Subjects on ND for 6 weeks mark-
edly improved their cardiovascular risk profile, including
lowering of LDL-C, insulin resistance, and blood pressure
[19] and it is possible that this improvement affected the
levels of cathepsin S. Our study supports such findings
since adjustment for change in LDL-C and total choles-
terol as well as change in body weight abolished the sig-
nificant difference between the groups.
Higher levels of circulating cathepsin S are associated
with insulin sensitivity [10]. In the current study we
could not find a correlation between changes in serum
cathepsin S and changes in HOMA-IR. However, the
change in insulin sensitivity induced by the 6-week ND
was moderate, albeit statistically significant [19]. Perhaps
the discrepancy also could be explained by insulin sensi-
tivity being measured with euglycemic clamp in the obser-
vational study, whereas it was estimated by HOMA-IR in
the present study.
The strengths of this study include the randomized
controlled design, and also all foods were provided to
the ND group ensuring high compliance and low drop-
out rates. It should however be noted that some of the
observed effect on cathepsin S levels was likely to be
caused by the fact that all foods was provided to the ND,
but not the control group. Also, these results cannot be
directly translated to clinical settings were dietary advice
alone is given. Further studies are needed where all
foods are provided to both ND and control groups, or
dietary advice is given to both groups. Although all sub-
jects in both groups were instructed to maintain their
physical activity level during the study, possible differ-
ences between groups in physical activity level and smo-
king were not assessed and may thus have introduced
some bias. Since only Caucasian Swedish subjects were
included, generalizability to other ethnic groups is un-
clear. Further, it should be noted that this is a post-hoc
study of the NORDIET trial, and thus there was noncentrations and changes in weight and cardiometabolic









s are adjusted for sex. HOMA -IR: Homeostasis model assessment-insulin
ein cholesterol, TG: Triglycerides, SB P: Systolic blood pressure, DBP: Diastolic
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Conclusion
These results suggest that a prudent diet comprising
healthy Nordic foods may moderately reduce cathepsin
S levels in non-obese men and women. This association
seems to be partly, mediated by diet-induced weight loss
and/or reduced LDL-C concentrations. Given the close
link between cathepsin S and various obesity-linked dis-
eases and increased mortality risk, the present results
warrant further investigation in further studies.
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